The intracellular signalosome of PD-L1 in cancer cells

被引：221

作者：

Escors, David ^{[1
,2
]}

Gato-Canas, Maria ^{[1
]}

Zuazo, Miren ^{[1
]}

Arasanz, Hugo ^{[1
,3
]}

Jesus Garcia-Granda, Maria ^{[1
]}

Vera, Ruth ^{[3
]}

Kochan, Grazyna ^{[1
]}

机构：

[1] Complejo Hosp Navarra, IdISNA, Navarrabiomed, Irunlarrea 3, Pamplona 31008, Navarra, Spain

[2] UCL, Rayne Inst, Div Infect & Immun, 5 Univ St, London WC1E 6JF, England

[3] Complejo Hosp Navarra, IdISNA, Oncol Dept, Irunlarrea 3, Pamplona 31008, Navarra, Spain

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2018年 / 3卷

关键词：

T-CELLS; B7-H1; EXPRESSION; TUMOR-CELLS; B7; FAMILY; IFN-GAMMA; PROGRAMMED CELL-DEATH-1; ACQUIRED-RESISTANCE; SIGNALING PATHWAYS; CARCINOMA PATIENTS; DOWN-MODULATION;

D O I：

10.1038/s41392-018-0022-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1. Second, PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival, regulate stress responses and confer resistance toward pro-apoptotic stimuli, such as interferons. Here, we review the current knowledge on intracellular signal transduction pathways regulated by PD-L1, describe its associated signalosome and discuss potential combinations of targeted therapies against the signalosome with PD-L1/PD-1 blockade therapies.

引用

页数：9

共 113 条

[71] Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers [J].

Nakanishi, Juro ;

Wada, Yoshihiro ;

Matsumoto, Koichiro ;

Azuma, Miyuki ;

Kikuchi, Ken ;

Ueda, Shoichi .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (08) :1173-1182

[72] PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma [J].

Nghiem, Paul T. ;

Bhatia, Shailender ;

Lipson, Evan J. ;

Kudchadkar, Ragini R. ;

Miller, Natalie J. ;

Annamalai, Lakshmanan ;

Berry, Sneha ;

Chartash, Elliot K. ;

Daud, Adil ;

Fling, Steven P. ;

Friedlander, Philip A. ;

Kluger, Harriet M. ;

Kohrt, Holbrook E. ;

Lundgren, Lisa ;

Margolin, Kim ;

Mitchell, Alan ;

Olencki, Thomas ;

Pardoll, Drew M. ;

Reddy, Sunil A. ;

Shantha, Erica M. ;

Sharfman, William H. ;

Sharon, Elad ;

Shemanski, Lynn R. ;

Shinohara, Michi M. ;

Sunshine, Joel C. ;

Taube, Janis M. ;

Thompson, John A. ;

Townson, Steven M. ;

Yearley, Jennifer H. ;

Topalian, Suzanne L. ;

Cheever, Martin A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (26) :2542-2552

[73] Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells [J].

Noh, Hyangsoon ;

Hu, Jiemiao ;

Wang, Xiaohong ;

Xia, Xueqing ;

Satelli, Arun ;

Li, Shulin .

CELL COMMUNICATION AND SIGNALING, 2015, 13

[74] PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation [J].

Noman, Muhammad Zaeem ;

Desantis, Giacomo ;

Janji, Bassam ;

Hasmim, Meriem ;

Karray, Saoussen ;

Dessen, Philippe ;

Bronte, Vincenzo ;

Chouaib, Salem .

JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 211 (05) :781-790

[75] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer [J].

Ohigashi, Y ;

Sho, M ;

Yamada, Y ;

Tsurui, Y ;

Hamada, K ;

Ikeda, N ;

Mizuno, T ;

Yoriki, R ;

Kashizuka, H ;

Yane, K ;

Tsushima, F ;

Otsuki, N ;

Yagita, H ;

Azuma, M ;

Nakajima, Y .

CLINICAL CANCER RESEARCH, 2005, 11 (08) :2947-2953

[76] Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer [J].

Ota, Keiichi ;

Azuma, Koichi ;

Kawahara, Akihiko ;

Hattori, Satoshi ;

Iwama, Eiji ;

Tanizaki, Junko ;

Harada, Taishi ;

Matsumoto, Koichiro ;

Takayama, Koichi ;

Takamori, Shinzo ;

Kage, Masayoshi ;

Hoshino, Tomoaki ;

Nakanishi, Yoichi ;

Okamoto, Isamu .

CLINICAL CANCER RESEARCH, 2015, 21 (17) :4014-4021

[77] Glucose metabolism regulatesT cell activation, differentiation, and functions [J].

Palmer, Clovis S. ;

Ostrowski, Matias ;

Balderson, Brad ;

Christian, Nicole ;

Crowe, Suzanne M. .

FRONTIERS IN IMMUNOLOGY, 2015, 6

[78] Inhibition of PI4K IIIα radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model [J].

Park, Younghee ;

Park, Ji Min ;

Kim, Dan Hyo ;

Kwon, Jeanny ;

Kim, In Ah .

ONCOTARGET, 2017, 8 (66) :110392-110405

[79] Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma [J].

Parsa, Andrew T. ;

Waldron, James S. ;

Panner, Amith ;

Crane, Courtney A. ;

Parney, Ian F. ;

Barry, Jeffrey J. ;

Cachola, Kristine E. ;

Murray, Joseph C. ;

Tihan, Tarik ;

Jensen, Michael C. ;

Mischel, Paul S. ;

Stokoe, David ;

Pieper, Russell O. .

NATURE MEDICINE, 2007, 13 (01) :84-88

[80] PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation [J].

Patsoukis, Nikolaos ;

Bardhan, Kankana ;

Chatterjee, Pranam ;

Sari, Duygu ;

Liu, Bianling ;

Bell, Lauren N. ;

Karoly, Edward D. ;

Freeman, Gordon J. ;

Petkova, Victoria ;

Seth, Pankaj ;

Li, Lequn ;

Boussiotis, Vassiliki A. .

NATURE COMMUNICATIONS, 2015, 6

← 3 4 5 6 7 8 9 10 11 12 →